NEWNow you can hearken to Fox Information articles!
Months after revealing his stage 4 cancer diagnosis, former U.S. Sen. Ben Sasse is talking out about an experimental remedy that might prolong his life.
Sasse, a Republican who represented Nebraska between 2015 and 2023, shared in December 2025 that he has metastatic pancreatic most cancers, which has unfold to a number of organs — together with his liver and lungs.
After initially being given three to 4 months to reside, Sasse, 54, entered a clinical trial for a drug referred to as daraxonrasib, an oral remedy (tablet) that’s designed to dam the faulty gene that triggers uncontrolled mobile development.
CANCER SURVIVAL APPEARS TO DOUBLE WITH COMMON VACCINE, RESEARCHERS SAY
The California-based drugmaker, Revolution Medicines, lately shared information from a section 3 medical trial of individuals with metastatic pancreatic cancer who didn’t reply to plain chemotherapy.
Sufferers on the therapy lived a median of 13 months, in comparison with round six months for many who continued with chemo.
Former Sen. Ben Sasse of Nebraska entered a medical trial for a drug referred to as daraxonrasib, an oral remedy (tablet) that’s designed to dam the faulty gene that triggers uncontrolled mobile development. (Anna Moneymaker/Getty Photographs)
“I’ve a lot, a lot much less ache than I had 4 months in the past after I was identified, and I’ve a large 76% discount in tumor quantity over the past 4 months,” Sasse informed “60 Minutes” in a current interview.
Daraxonrasib works by going after a key development “change” in lots of cancers referred to as RAS, in response to Sarbajit Mukherjee, M.D., chief of gastrointestinal medical oncology at Miami Most cancers Institute, a part of Baptist Well being South Florida.
MAN WITH STAGE 4 CANCER RAISES $150K FOR EXPERIMENTAL TREATMENT
“In pancreatic most cancers, that change is caught within the ‘on’ place within the overwhelming majority of tumors, always telling the most cancers cells to develop and unfold,” the physician, who was not concerned within the trial and didn’t deal with Sasse, informed Fox Information Digital.
“Daraxonrasib is designed to bind to RAS in its energetic state and switch down that sign, which might gradual or shrink the most cancers.”
“The drug is within the ultimate levels of medical trials, the place it has been proven to double the survival of these beforehand handled for metastatic pancreatic most cancers.”
Pancreatic most cancers is tough to diagnose early as a result of there are typically no signs — or solely delicate gastrointestinal signs — till it’s already widespread, in response to Dr. Marc Siegel, Fox Information senior medical analyst.
“That is the first-of-its-kind focused remedy for pancreatic most cancers,” Siegel, who additionally was not concerned within the analysis or the senator’s therapy, informed Fox Information Digital. “The drug is within the ultimate levels of medical trials, the place it has been proven to double the survival of these beforehand handled for metastatic pancreatic most cancers.”
Sasse, proven above, introduced his prognosis late final 12 months. An skilled famous that the survival enhance seen from the medical trial is a “massive distinction” for a illness that usually has a lot shorter survival instances. (Win McNamee/Getty Photographs)
Mukherjee famous that the survival enhance seen within the trial is a “massive distinction” for a illness that usually has a lot shorter survival instances.
“From my perspective, as somebody who treats pancreatic most cancers day-after-day, daraxonrasib is the first targeted pill on this illness that actually appears like a step change reasonably than a small incremental enchancment,” he mentioned.
“It opens the door to rather more personalised methods going ahead. For a most cancers the place progress has been painfully gradual, it may reshape how we take care of sufferers with superior illness.”
RECTAL CANCER DEATHS RISING UP TO THREE TIMES FASTER IN SPECIFIC AGE GROUP, STUDY FINDS
Whereas present chemotherapy choices can shrink pancreatic tumors and assist individuals reside longer, they’re “robust,” Mukherjee famous — “and as soon as they cease working, our choices are restricted and survival is usually measured in just some extra months.”
Early information additionally means that when daraxonrasib is mixed with customary chemotherapy as the primary therapy, there may be extra shrinkage of tumors and extra sufferers doing nicely at six months than they usually would solely with chemotherapy.
Sasse shared in December 2025 that he has metastatic pancreatic most cancers, which has unfold to a number of organs, together with his liver and lungs. (Meghan McCarthy/Palm Seaside Day by day Information/USA TODAY NETWORK by way of Imagn Photographs)
If the drug is permitted, it should probably turn into an vital choice for sufferers when customary chemotherapy stops working, Mukherjee urged.
“Ongoing trials at the moment are asking whether or not it must also be used as a part of the very first therapy plan,” he added.
NEW CANCER VACCINE SHOWS PROMISING RESULTS FOR CERTAIN PATIENTS
Though the drug is described as “well-tolerated” in comparison with chemotherapy, the physician famous that, like all robust most cancers drug, daraxonrasib has unintended effects.
“Those we see most frequently embody rash, diarrhea, mouth sores and fatigue, with sufferers needing common blood exams and shut observe‑up whereas on therapy,” Mukherjee mentioned.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Within the medical trials, most of those issues have been managed by adjusting the dose or including supportive drugs.
“The constraints are vital to be clear about — it’s nonetheless not but FDA‑permitted, and it isn’t a treatment,” Mukherjee famous.
Along with the daraxonrasi, Sasse credit his religion for serving to him beat his unique prognosis. (Drew Angerer/Getty Photographs)
“Over time, most cancers will ultimately discover methods to develop across the drug.”
CLICK HERE FOR MORE HEALTH STORIES
Along with daraxonrasib, which he calls a “miracle” drug, Sasse credits his faith for serving to him beat his unique prognosis.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“It is bizarre to be in your early 50s and get a terminal prognosis, and folks swiftly act such as you’re 93 or 94, and you’ve got a variety of knowledge,” he mentioned.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“I do not know that I’ve a variety of knowledge, however I’ve a variety of issues that I believe we ought to be reflecting on collectively.”
Fox Information Digital reached out to Sasse for additional remark, and to the pinnacle of the medical trial as nicely.
